- Home
- SFWL vs ACET Comparison
SFWL vs ACET Comparison
Compare SFWL & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- ACET
- Stock Information
- Founded
- SFWL 2001
- ACET 1947
- Country
- SFWL China
- ACET United States
- Employees
- SFWL N/A
- ACET N/A
- Industry
- SFWL Trucking Freight/Courier Services
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- ACET Health Care
- Exchange
- SFWL Nasdaq
- ACET Nasdaq
- Market Cap
- SFWL 81.0M
- ACET 64.9M
- IPO Year
- SFWL 2023
- ACET N/A
- Fundamental
- Price
- SFWL $1.00
- ACET $0.76
- Analyst Decision
- SFWL
- ACET Buy
- Analyst Count
- SFWL 0
- ACET 6
- Target Price
- SFWL N/A
- ACET $6.00
- AVG Volume (30 Days)
- SFWL 9.3K
- ACET 419.0K
- Earning Date
- SFWL 09-04-2025
- ACET 08-12-2025
- Dividend Yield
- SFWL N/A
- ACET N/A
- EPS Growth
- SFWL 4.79
- ACET N/A
- EPS
- SFWL 0.13
- ACET N/A
- Revenue
- SFWL $504,158,000.00
- ACET N/A
- Revenue This Year
- SFWL N/A
- ACET N/A
- Revenue Next Year
- SFWL N/A
- ACET N/A
- P/E Ratio
- SFWL $7.46
- ACET N/A
- Revenue Growth
- SFWL 24.75
- ACET N/A
- 52 Week Low
- SFWL $0.86
- ACET $0.45
- 52 Week High
- SFWL $1.60
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- SFWL 54.48
- ACET 53.73
- Support Level
- SFWL $0.96
- ACET $0.58
- Resistance Level
- SFWL $1.02
- ACET $0.72
- Average True Range (ATR)
- SFWL 0.05
- ACET 0.04
- MACD
- SFWL 0.00
- ACET 0.01
- Stochastic Oscillator
- SFWL 90.91
- ACET 88.89
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.